On this September 11, we pause to honor the memory of those we lost and express our gratitude to the heroes who emerged in the face of unimaginable tragedy. It's a reminder of the resilience, unity, and compassion that can arise in the darkest of times. #NeverForget #September11 #Resilience
ImmPACT Bio
生物技术研究
West Hills，California 7,692 位关注者
We are developing advanced therapies for cancer patients with critical unmet needs
关于我们
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. Our technology is designed to precisely distinguish cancer and diseased cells from normal cells; thereby eliminating them without damaging normal tissues. The company was founded in 2017 in the FuturRx incubator (Israel). In 2019, ImmPACT Bio was incorporated in the US. In 2021 ImmPACT Bio merged with Kalthera. In 2022 we moved our Corporate offices to West Hills, CA and built a state-of-the-art clinical manufacturing facility.
- 网站
-
immpactbio.com
ImmPACT Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- West Hills，California
- 类型
- 私人持股
- 创立
- 2017
- 领域
- CAR-T、Immunotherapy、Cancer Therapy、On target off tumor toxicity 、Selective treatment 、Logic gate、Oncology、Biotechnology、Research、Immunotherapy、autoimmune和lupus
地点
ImmPACT Bio员工
-
Ofir Goldberger ??
Biotech Corporate / Business Development and Licensing
-
Sheila Gujrathi, MD
Biotech Executive | Physician Scientist | Healthcare Investor | Drug Developer
-
Carolyn Gabus
Senior Director, Clinical Operations at ImmPACT Bio
-
Sumant Ramachandra, M.D., Ph.D.
CEO & Board Director at ImmPACT Bio
动态
-
Welcome to the ImmPACT Bio team, Marcia Friedman, M.D.! #welcometotheteam, #cartcelltherapy, #MakeAnImmPACT
-
-
ImmPACT Bio is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted IND clearance for IMPT-514, a bispecific CAR T therapy, as a potential treatment of adult patients with #multiplesclerosis (MS). This dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and the potential to reset the immune system. Read the press release: https://bit.ly/3YRCr1q #CARTcelltherapy, #celltherapy, #autoimmunedisease
-
-
Welcome to the ImmPACT Bio team, Amanda Squires! #Welcometotheteam, #CARTcelltherapy, #MakeAnImmPACT
-
-
Yesterday we honored Juneteenth, the day ALL Americans became free. We celebrate the victories of the past and remain dedicated to pushing for a more equitable future. #juneteenth #progress #equality
-
-
Happy Pride Month from ImmPACT Bio!????Celebrating love, diversity, and equality. #PrideMonth, #DiversityAndInclusion, #MakeAnImmPACT
-
-
ImmPACT Bio is a proud sponsor of the upcoming LA Bioscience Ecosystem Summit Twenty24 (LA BEST 2024) hosted by the UCLA Technology Development Group on May 23, 2024.? ? #LABest, #MakeAnImmPACT
-
-
We are pleased to announce that ImmPACT Bio will be presenting new preclinical data for our innovative CD19/20 bispecific CAR-T cell therapy, IMPT-514, at the upcoming Consortium of Multiple Sclerosis (MS) Centers Annual Meeting in Nashville, TN, from May 28 – June 1, 2024. ?? Presentation Details: Title: Manufacturing of CD19/20 Bispecific CAR-T Cell Therapy (IMPT-514) for the Treatment of Multiple Sclerosis Abstract Number: LB04 Presenter: Ethan BenDavid, ImmPACT Bio Poster Session Date/Time: Thursday, May 30, 2024, from 5:15 – 7:15 PM ET Location: Music City Center, Exhibit Hall AB Read our press release:?https://lnkd.in/gRxjTupN #ImmPACTBio #CAR_TCellTherapy #MultipleSclerosis #MSResearch #CMSC2024 #Biotechnology #Innovation #Healthcare
-
-
The ImmPACT Bio team recently attended the?LuCIN?Annual Meeting held by the Lupus Research Alliance. This inspiring event provided an opportunity for our team to meet with patients and share information about?our?clinical trials with the #lupus community. Thank you #TeamImmPACT https://lnkd.in/gma9dfAP #LupusAwarenessMonth?#LupusClinicalResearch?#MakeAnIMMPACT
-